Generate Biomedicines, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Generate Biomedicines announced third quarter 2026 financial results, highlighting progress in severe asthma and COPD drug candidates, new collaborations, and a cash runway into early 2028.